"How much money is going into healthcare AI?" has at least three credible answers at any moment, and they can differ by a factor of three. This tracker holds the disclosed record — the venture totals, AI's share of them, and the acquisitions — from the three primary sources that publish methodology: Rock Health, CB Insights, and Silicon Valley Bank. Every figure is dated, scoped, and tied to a numbered source. As of July 2026.
Three trackers, three totals
The most common error in funding commentary is quoting two trackers as if they measured the same market. For 2025, all three are worth holding side by side:
| Tracker | Scope | 2025 total | Deals | Source |
|---|---|---|---|---|
| Rock Health | US digital health venture | $14.2B | 482 | 1 |
| CB Insights | Global digital health | $22.3B | 1,474 | 4 |
| Silicon Valley Bank | All US/EU healthcare venture | $46.8B | — | 5 |
Rock Health's $14.2B was up 35% on its re-based 2024 figure of $10.5B, on slightly fewer deals — average deal size jumped to $29.3M from $20.7M 1. CB Insights saw the same shape globally: funding up 19% to $22.3B while deal count fell 9%, with mega-rounds of $100M+ taking 44% of all dollars across just 48 deals 4. SVB's wider healthcare lens ran the other way — $46.8B total, down 12% year over year — which means AI's rise happened inside a shrinking overall pool 5. Fewer, larger, AI-centered checks is the single consistent story across all three.
How much of the money goes to AI?
2025 is likely the last year the "AI share" statistic exists in clean form. Rock Health counted 54% of US digital health dollars going to AI-enabled startups, up from 37% in 2024, with an approximately 19% premium on average deal size 12. SVB counted more than $18B into healthcare AI — 46% of all healthcare investment — and recorded more $300M+ healthcare AI deals than in any prior year, with those outsized rounds alone making up 40% of healthcare AI dollars 5. CB Insights' marker was starker: every one of 2025's 14 new digital health unicorns — Abridge and Hippocratic AI among them — builds on AI, triple 2024's unicorn count 4.
Then the statistic dissolved. In 2026 Rock Health stopped labeling startups "AI-enabled" at all, "as AI has become sufficiently ubiquitous and no longer a distinguishing product or strategy" 3. When the lead tracker retires the label, the meaningful question shifts from how much goes to AI to which layer of AI the money backs — the foundation model platforms, the workflow tools like the ambient AI scribe, or the diagnostics that show up in our FDA device tracker.
What does the 2026 half-year picture show?
H1 2026 brought $7.4B across 244 US digital health deals — $1B ahead of H1 2025 on a nearly identical deal count 3. Concentration deepened again: 19 companies raised 20 megadeals, absorbing 45% of all capital (from 42% in 2025 and 22% in 2024), while the median deal rose to $14M, a high since 2022 3. Disclosed rounds on the AI-heavy end included radiology AI firm Aidoc collecting its second $150M check in under a year 3. The exit window cracked open too: Oura — whose $900M late-2025 raise was the sector's largest round since 2011 1 — was the only digital health company to file for an IPO in 2026's first half 3.
M&A: from drought to the busiest quarter in five years
The acquisition cycle turned faster than the funding cycle. 2024 marked a decade low of 118 digital health M&A deals 2; 2025 ran 61% hotter 1, a pace the mid-year report tallies at 199 deals once late-surfacing transactions were counted 3. H1 2026 added 115 acquisitions, 71 of them announced in Q2 alone — the busiest quarter since Q3 2021 3. Private equity did disproportionate work: roughly 10% of 2025's deals but a near-600% increase in spend over 2024 1. And by CB Insights' count, AI targets made up 24% of digital health M&A activity in 2025 4.
The headline strategic deal of 2026 so far is Roche's definitive merger agreement, announced 7 May 2026, to acquire digital pathology and AI company PathAI for $750M upfront plus up to $300M in milestone payments, with closing expected in the second half of 2026 6. It is the clearest disclosed data point yet on what an established diagnostics buyer will pay for a clinical AI platform rather than a pilot.
How to read these numbers
Five cautions travel with every figure here. Scope drives the totals — before comparing two numbers, check whether they cover US digital health, global digital health, or all healthcare venture. Trackers revise: Rock Health's 2024 print of $10.1B across 497 deals 2 became $10.5B across 509 in the following year-end report 1, and its 2025 M&A count moved from the year-end tally to 199 by mid-2026 3 — so the report date matters as much as the period covered. Only disclosed deals are counted, which understates quiet rounds and unannounced acquisitions. "AI-enabled" was always a labeling judgement, and its retirement in 2026 3 means the AI-share series ends at 2025 rather than continuing cleanly. And deal values are announcements — milestone payments, like the $300M tail on the PathAI agreement 6, may never fully pay out.
We revisit this page on a ninety-day cycle and whenever a new tracker report or a disclosed deal above $500M lands. For the wider dashboard this capital feeds — adoption, evidence, and regulation — start at the AI in healthcare statistics hub, and for what the best-funded category actually does in the clinic, see the AI scribe adoption tracker.